Pfizer, Astellas Execs Talk Deals At BIO Asia
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Although the economic slump may seem like an opportune time for more mergers and acquisitions with big pharmas taking over biotechs, there are challenges to such an approach, pharma executives told attendees of the annual BIO Asia partnering conference Jan. 19
You may also be interested in...
Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics
In a surprise move spurred by a desire to own a greater share of the promising angina drug Ranexa, Astellas announced Jan. 27 its hostile offer for partner CV Therapeutics in a cash deal worth roughly $1 billion
Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics
In a surprise move spurred by a desire to own a greater share of the promising angina drug Ranexa, Astellas announced Jan. 27 its hostile offer for partner CV Therapeutics in a cash deal worth roughly $1 billion
With Wyeth, Pfizer To Become Second-largest Multinational Pharma In India
MUMBAI - Pfizer's mega buyout of Wyeth for $68 billion is set to further strengthen the Indian businesses of the world's largest drug maker with additional focus on tapping the domestic formulations business and enhancing clinical trials